Conventional vs. Newer Antipsychotics in Elderly Patients
| Autor: | M. Jackuelyn Harris, Jonathan P. Lacro, Enid Rockwell, Dilip V. Jeste, James B. Lohr |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
medicine.medical_specialty
Pediatrics business.industry Cognition Antipsychotic treatment medicine.disease Tardive dyskinesia Lower risk humanities Psychiatry and Mental health Extrapyramidal symptoms Schizophrenia Medicine Dementia Dosing Geriatrics and Gerontology medicine.symptom business Psychiatry |
| Zdroj: | The American Journal of Geriatric Psychiatry. 7:70-76 |
| ISSN: | 1064-7481 |
| DOI: | 10.1097/00019442-199902000-00010 |
| Popis: | Elderly patients with schizophrenia and dementia patients with agitation are frequently candidates for antipsychotic treatment. Conventional neuroleptics have relatively little effect on negative symptoms and may cause considerable side effects, especially in elderly patients. The authors have found a 29% cumulative annual incidence of tardive dyskinesia (TD) in middle-aged and elderly outpatients treated with relatively low doses of conventional neuroleptics. Newer antipsychotics are less likely to cause extrapyramidal symptoms and may be associated with a lower risk of TD. They are generally effective for both positive and negative symptoms and may also improve some aspects of cognition, but these drugs have their own side effects. Dosing requirements for elderly patients tend to be much lower than those for younger adults. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|